Search
Exenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigationalIt activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control[L42690].
Fosdenopterin
go.drugbank.com/drugs/DB16628ApprovedBy improving the three-year survival rate from 55% to 84%,[L32288] and considering the lack of alternative therapies available, fosdenopterin appears poised to become a standard of therapy in the management … [A230088,A230593] In the past, management strategies for this disorder involved symptomatic and supportive treatment,[L32163] though efforts were made to develop a suitable exogenous replacement for the
Potassium perchlorate
go.drugbank.com/drugs/DB09418ApprovedWithdrawnThe therapeutic use of potassium perchlorate in thyroid disorders has been ceased due to a high risk for developing aplastic anemia and nephrotic syndrome [L2364].
Ammonium chloride
go.drugbank.com/drugs/DB06767ApprovedInvestigationalVet approvedAmmonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.
Mixtures: Cough Syr W Codeine Diphenhyd HCl & Ammon Cl, NO- TOC JARABESamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalSamidorphan has been shown in animal models and clinical trials to ameliorate [olanzapine]-induced weight gain and metabolic dysfunction. … [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigational[A31739] Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS … [L1199] In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo.
SQ-109
go.drugbank.com/drugs/DB05186InvestigationalCurrently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalThis condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. … [A189063] Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies.
Cefmenoxime
go.drugbank.com/drugs/DB00267ApprovedIt is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.
Omega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawnThe increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters.